Deferoxamine mesylate is utilized to treat iron poisoning, particularly in little children. It can also be used to treat hemochromatosis, a disease that causes iron accumulation that can be either hereditary or acquired.
Acquired hemochromatosis is normal in patients with particular kinds of chronic anemia, such as thalassemia and myelodysplastic disorders who require many blood transfusions, which can expand the amount of iron in the body.
Deferoxamine acts by restricting free iron in the circulatory system and improving its disposal in the urine. By expelling excess iron, it decreases the harm done to different organs and tissues, for example, the liver. Likewise, it speeds recuperation of nerve damage. Deferoxamine may change the expression and the release of inflammatory mediators.
